Annual EBIT
-$12.92 M
+$6.64 M+33.96%
December 1, 2023
Summary
- As of February 7, 2025, PSTV annual earnings before interest & taxes is -$12.92 million, with the most recent change of +$6.64 million (+33.96%) on December 1, 2023.
- During the last 3 years, PSTV annual EBIT has fallen by -$5.79 million (-81.12%).
- PSTV annual EBIT is now -804.83% below its all-time high of -$1.43 million, reached on December 31, 2019.
Performance
PSTV EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$2.81 M
-$3.44 M-545.09%
September 1, 2024
Summary
- As of February 7, 2025, PSTV quarterly earnings before interest & taxes is -$2.81 million, with the most recent change of -$3.44 million (-545.09%) on September 1, 2024.
- Over the past year, PSTV quarterly EBIT has increased by +$414.00 thousand (+12.83%).
- PSTV quarterly EBIT is now -152.23% below its all-time high of $5.39 million, reached on June 30, 2015.
Performance
PSTV Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$9.16 M
+$319.00 K+3.37%
September 1, 2024
Summary
- As of February 7, 2025, PSTV TTM earnings before interest & taxes is -$9.16 million, with the most recent change of +$319.00 thousand (+3.37%) on September 1, 2024.
- Over the past year, PSTV TTM EBIT has increased by +$2.32 million (+20.22%).
- PSTV TTM EBIT is now -1191.30% below its all-time high of $839.00 thousand, reached on March 31, 2016.
Performance
PSTV TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
PSTV EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +34.0% | +12.8% | +20.2% |
| 3 y3 years | -81.1% | +28.2% | +34.2% |
| 5 y5 years | -85.8% | +28.2% | +34.2% |
PSTV EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -3.6% | +34.0% | -545.1% | +48.9% | at high | +54.9% |
| 5 y | 5-year | -804.8% | +34.0% | -316.7% | +48.9% | -6682.2% | +54.9% |
| alltime | all time | -804.8% | +60.8% | -152.2% | +86.5% | -1191.3% | +79.4% |
Plus Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$2.81 M(-545.1%) | -$9.16 M(-3.4%) |
| Jun 2024 | - | $632.00 K(-119.6%) | -$9.47 M(-17.4%) |
| Mar 2024 | - | -$3.23 M(-13.9%) | -$11.48 M(-11.2%) |
| Dec 2023 | -$12.92 M(-34.0%) | -$3.75 M(+19.7%) | -$12.92 M(-11.9%) |
| Sep 2023 | - | -$3.13 M(+128.6%) | -$14.67 M(-11.5%) |
| Jun 2023 | - | -$1.37 M(-70.7%) | -$16.59 M(-18.4%) |
| Mar 2023 | - | -$4.67 M(-15.1%) | -$20.32 M(+3.8%) |
| Dec 2022 | -$19.56 M(+56.9%) | -$5.50 M(+9.0%) | -$19.56 M(+8.7%) |
| Sep 2022 | - | -$5.05 M(-1.1%) | -$18.00 M(+9.5%) |
| Jun 2022 | - | -$5.10 M(+30.2%) | -$16.44 M(+18.2%) |
| Mar 2022 | - | -$3.92 M(-0.3%) | -$13.91 M(+11.6%) |
| Dec 2021 | -$12.47 M(+74.8%) | -$3.93 M(+12.6%) | -$12.47 M(+5.0%) |
| Sep 2021 | - | -$3.49 M(+35.8%) | -$11.87 M(+20.5%) |
| Jun 2021 | - | -$2.57 M(+4.0%) | -$9.85 M(+11.1%) |
| Mar 2021 | - | -$2.47 M(-25.8%) | -$8.87 M(+24.3%) |
| Dec 2020 | -$7.13 M(+399.6%) | -$3.33 M(+126.0%) | -$7.13 M(+185.1%) |
| Sep 2020 | - | -$1.48 M(-7.1%) | -$2.50 M(+1753.3%) |
| Jun 2020 | - | -$1.59 M(+115.0%) | -$135.00 K(-38.1%) |
| Mar 2020 | - | -$738.00 K(-156.9%) | -$218.00 K(-84.7%) |
| Dec 2019 | -$1.43 M(-79.5%) | $1.30 M(+45.5%) | -$1.43 M(-65.9%) |
| Sep 2019 | - | $892.00 K(-153.4%) | -$4.19 M(-29.7%) |
| Jun 2019 | - | -$1.67 M(-14.3%) | -$5.97 M(-20.6%) |
| Mar 2019 | - | -$1.95 M(+32.9%) | -$7.51 M(-21.3%) |
| Dec 2018 | -$6.96 M(-66.3%) | -$1.47 M(+66.1%) | -$9.55 M(-19.9%) |
| Sep 2018 | - | -$883.00 K(-72.5%) | -$11.93 M(-22.4%) |
| Jun 2018 | - | -$3.21 M(-19.3%) | -$15.38 M(-13.0%) |
| Mar 2018 | - | -$3.99 M(+3.8%) | -$17.67 M(-14.4%) |
| Dec 2017 | -$20.64 M(+6.1%) | -$3.84 M(-11.4%) | -$20.64 M(-2.1%) |
| Sep 2017 | - | -$4.33 M(-21.4%) | -$21.07 M(-1.9%) |
| Jun 2017 | - | -$5.51 M(-20.7%) | -$21.48 M(-1.1%) |
| Mar 2017 | - | -$6.95 M(+62.7%) | -$21.73 M(+11.7%) |
| Dec 2016 | -$19.45 M(+26.6%) | -$4.27 M(-9.8%) | -$19.45 M(+12.8%) |
| Sep 2016 | - | -$4.74 M(-17.7%) | -$17.24 M(+67.3%) |
| Jun 2016 | - | -$5.76 M(+23.0%) | -$10.31 M(-1328.5%) |
| Mar 2016 | - | -$4.68 M(+127.2%) | $839.00 K(-105.5%) |
| Dec 2015 | -$15.37 M(-53.4%) | -$2.06 M(-193.9%) | -$15.37 M(-14.5%) |
| Sep 2015 | - | $2.20 M(-59.2%) | -$17.98 M(-36.5%) |
| Jun 2015 | - | $5.39 M(-125.8%) | -$28.30 M(-36.3%) |
| Mar 2015 | - | -$20.89 M(+347.1%) | -$44.42 M(+34.6%) |
| Dec 2014 | -$33.00 M(+44.8%) | -$4.67 M(-42.5%) | -$33.00 M(-11.8%) |
| Sep 2014 | - | -$8.13 M(-24.4%) | -$37.43 M(+11.8%) |
| Jun 2014 | - | -$10.74 M(+13.6%) | -$33.47 M(+32.4%) |
| Mar 2014 | - | -$9.46 M(+3.9%) | -$25.28 M(+11.0%) |
| Dec 2013 | -$22.78 M(-21.2%) | -$9.10 M(+118.5%) | -$22.78 M(+36.4%) |
| Sep 2013 | - | -$4.16 M(+62.7%) | -$16.70 M(-27.2%) |
| Jun 2013 | - | -$2.56 M(-63.2%) | -$22.93 M(-16.3%) |
| Mar 2013 | - | -$6.96 M(+130.4%) | -$27.39 M(-5.2%) |
| Dec 2012 | -$28.89 M | -$3.02 M(-70.9%) | -$28.89 M(-0.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2012 | - | -$10.39 M(+48.0%) | -$29.07 M(+5.8%) |
| Jun 2012 | - | -$7.02 M(-17.0%) | -$27.47 M(-8.6%) |
| Mar 2012 | - | -$8.46 M(+164.9%) | -$30.06 M(+1.3%) |
| Dec 2011 | -$29.67 M(+16.6%) | -$3.19 M(-63.7%) | -$29.67 M(-15.7%) |
| Sep 2011 | - | -$8.79 M(-8.6%) | -$35.20 M(-2.2%) |
| Jun 2011 | - | -$9.62 M(+19.3%) | -$36.01 M(+14.6%) |
| Mar 2011 | - | -$8.06 M(-7.7%) | -$31.43 M(+23.5%) |
| Dec 2010 | -$25.44 M(+18.1%) | -$8.73 M(-9.0%) | -$25.44 M(-1.3%) |
| Sep 2010 | - | -$9.59 M(+90.2%) | -$25.78 M(+14.0%) |
| Jun 2010 | - | -$5.04 M(+142.9%) | -$22.61 M(+25.6%) |
| Mar 2010 | - | -$2.08 M(-77.1%) | -$18.00 M(-16.4%) |
| Dec 2009 | -$21.55 M(-27.6%) | -$9.07 M(+41.2%) | -$21.52 M(+15.1%) |
| Sep 2009 | - | -$6.42 M(+1397.4%) | -$18.71 M(-5.2%) |
| Jun 2009 | - | -$429.00 K(-92.3%) | -$19.74 M(-28.7%) |
| Mar 2009 | - | -$5.60 M(-10.4%) | -$27.68 M(-9.0%) |
| Dec 2008 | -$29.76 M(-5.1%) | -$6.25 M(-16.2%) | -$30.41 M(-24.4%) |
| Sep 2008 | - | -$7.46 M(-10.9%) | -$40.20 M(+4.8%) |
| Jun 2008 | - | -$8.37 M(+0.5%) | -$38.36 M(+6.2%) |
| Mar 2008 | - | -$8.33 M(-48.1%) | -$36.10 M(-1.3%) |
| Dec 2007 | -$31.35 M(+61.8%) | -$16.05 M(+186.1%) | -$36.58 M(+127.5%) |
| Sep 2007 | - | -$5.61 M(-8.3%) | -$16.08 M(-16.8%) |
| Jun 2007 | - | -$6.12 M(-30.6%) | -$19.34 M(-6.3%) |
| Mar 2007 | - | -$8.81 M(-297.8%) | -$20.65 M(+6.5%) |
| Dec 2006 | -$19.38 M(-29.9%) | $4.45 M(-150.2%) | -$19.38 M(-42.5%) |
| Sep 2006 | - | -$8.87 M(+19.4%) | -$33.71 M(+3.1%) |
| Jun 2006 | - | -$7.42 M(-1.5%) | -$32.71 M(+6.8%) |
| Mar 2006 | - | -$7.54 M(-23.7%) | -$30.64 M(+10.9%) |
| Dec 2005 | -$27.63 M(+78.7%) | -$9.88 M(+25.5%) | -$27.63 M(+26.3%) |
| Sep 2005 | - | -$7.87 M(+47.1%) | -$21.87 M(+19.3%) |
| Jun 2005 | - | -$5.35 M(+18.1%) | -$18.33 M(+9.6%) |
| Mar 2005 | - | -$4.53 M(+9.8%) | -$16.73 M(+6.5%) |
| Dec 2004 | -$15.46 M(+67.9%) | -$4.12 M(-4.7%) | -$15.70 M(+22.8%) |
| Sep 2004 | - | -$4.33 M(+15.3%) | -$12.79 M(+17.5%) |
| Jun 2004 | - | -$3.75 M(+7.0%) | -$10.89 M(+17.1%) |
| Mar 2004 | - | -$3.50 M(+189.1%) | -$9.30 M(+0.9%) |
| Dec 2003 | -$9.21 M(-19.9%) | -$1.21 M(-50.0%) | -$9.21 M(-20.3%) |
| Sep 2003 | - | -$2.42 M(+12.3%) | -$11.56 M(-4.3%) |
| Jun 2003 | - | -$2.16 M(-36.8%) | -$12.08 M(+2.9%) |
| Mar 2003 | - | -$3.42 M(-4.2%) | -$11.74 M(+2.1%) |
| Dec 2002 | -$11.50 M(+0.6%) | -$3.56 M(+21.3%) | -$11.50 M(+23.4%) |
| Sep 2002 | - | -$2.94 M(+61.7%) | -$9.32 M(-2.8%) |
| Jun 2002 | - | -$1.82 M(-42.8%) | -$9.59 M(-24.6%) |
| Mar 2002 | - | -$3.18 M(+129.0%) | -$12.71 M(+33.3%) |
| Dec 2001 | -$11.43 M(+19.0%) | -$1.39 M(-56.7%) | -$9.53 M(+17.0%) |
| Sep 2001 | - | -$3.20 M(-35.2%) | -$8.14 M(+64.8%) |
| Jun 2001 | - | -$4.94 M | -$4.94 M |
| Dec 2000 | -$9.61 M(+114.7%) | - | - |
| Dec 1999 | -$4.47 M(+117.5%) | - | - |
| Dec 1998 | -$2.06 M | - | - |
FAQ
- What is Plus Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Plus Therapeutics?
- What is Plus Therapeutics annual EBIT year-on-year change?
- What is Plus Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Plus Therapeutics?
- What is Plus Therapeutics quarterly EBIT year-on-year change?
- What is Plus Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Plus Therapeutics?
- What is Plus Therapeutics TTM EBIT year-on-year change?
What is Plus Therapeutics annual earnings before interest & taxes?
The current annual EBIT of PSTV is -$12.92 M
What is the all time high annual EBIT for Plus Therapeutics?
Plus Therapeutics all-time high annual earnings before interest & taxes is -$1.43 M
What is Plus Therapeutics annual EBIT year-on-year change?
Over the past year, PSTV annual earnings before interest & taxes has changed by +$6.64 M (+33.96%)
What is Plus Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of PSTV is -$2.81 M
What is the all time high quarterly EBIT for Plus Therapeutics?
Plus Therapeutics all-time high quarterly earnings before interest & taxes is $5.39 M
What is Plus Therapeutics quarterly EBIT year-on-year change?
Over the past year, PSTV quarterly earnings before interest & taxes has changed by +$414.00 K (+12.83%)
What is Plus Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of PSTV is -$9.16 M
What is the all time high TTM EBIT for Plus Therapeutics?
Plus Therapeutics all-time high TTM earnings before interest & taxes is $839.00 K
What is Plus Therapeutics TTM EBIT year-on-year change?
Over the past year, PSTV TTM earnings before interest & taxes has changed by +$2.32 M (+20.22%)